PRESS RELEASES

Date Title and Summary View
Toggle Summary FORMER GLAXO SMITH KLINE CHIEF MEDICAL OFFICER PETER G. TRABER, M.D., NAMED CHIEF MEDICAL OFFICER OF PRO-PHARMACEUTICALS
Dr. Traber Will Lead Design of Phase lll Colorectal Cancer Trial for DAVANAT® and the Company's FDA Approval Strategy
View HTML
Toggle Summary PRO-PHARMACEUTICALS PREPARES PHASE III DAVANAT® TRIAL FOR SECOND HALF 2010
Peter G. Traber, M.D. Joins Trial Design Team to Finalize and Implement Strategy for FDA Approval
View HTML
Toggle Summary PRO-PHARMACEUTICALS REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS View HTML
Toggle Summary PRO-PHARMACEUTICALS CLOSES FINAL $570,000 TRANCHE FROM 10X FUND TO COMPLETE $6 MILLION RAISE View HTML
Toggle Summary PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE FROM 10X FUND View HTML
Toggle Summary COLOMBIAN PRESIDENT URIBE WELCOMES PRO-PHARMACEUTICALS AND INTRODUCTION OF DAVANAT® TO COLOMBIA View HTML
Toggle Summary PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2009 FINANCIAL RESULTS View HTML
Toggle Summary PRO-PHARMACEUTICALS CLOSES $335,000 TRANCHE View HTML
Toggle Summary PRO-PHARMACEUTICALS RECEIVES FINAL TRANCHE OF FUNDING FROM FEDERAL GRANT; RAISES CASH POSITION TO $8 MILLION View HTML
Toggle Summary PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE View HTML